Dice Therapeutics, Inc. DICE
We take great care to ensure that the data presented and summarized in this overview for DICE Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in DICE
Top Purchases
Top Sells
About DICE
DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17, which is a validated drug target implicated in a various immunology indications. It is also developing oral therapeutic candidates targeting a4ß7 integrin for the treatment of inflammatory bowel diseases, as well as targeting aVß1/aVß6 integrin for the treatment of idiopathic pulmonary fibrosis. In addition, the company focuses on immuno-oncology for antibody therapeutics. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
Insider Transactions at DICE
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 09
2023
|
Ra Capital Management, L.P. |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
7,856,612
-100.0%
|
-
|
|
Aug 09
2023
|
Sharon Tetlow Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
49,841
-100.0%
|
-
|
|
Aug 09
2023
|
Scott M. Robertson CFO & CBO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
198,000
-100.0%
|
-
|
|
Aug 09
2023
|
James Paul Scopa Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
25,722
-100.0%
|
-
|
|
Aug 09
2023
|
James Paul Scopa Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
15,199
-100.0%
|
-
|
|
Aug 09
2023
|
Kevin Judice CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
799,685
-100.0%
|
-
|
|
Aug 09
2023
|
Lu Timothy CMO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
152,285
-100.0%
|
-
|
|
Aug 09
2023
|
Richard H Scheller Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
8,427
-100.0%
|
-
|
|
Aug 09
2023
|
John R. Jacobsen CSO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
147,497
-100.0%
|
-
|
|
Aug 02
2023
|
James Paul Scopa Director |
SELL
Bona fide gift
|
Indirect |
2,420
-4.33%
|
-
|
|
Jul 18
2023
|
James Paul Scopa Director |
SELL
Bona fide gift
|
Indirect |
2,200
-7.25%
|
-
|
|
Jul 11
2023
|
James Paul Scopa Director |
SELL
Bona fide gift
|
Indirect |
300
-0.98%
|
-
|
|
Jun 22
2023
|
Northpond Ventures Gp, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
2,492,871
-75.77%
|
$114,672,066
$46.5 P/Share
|
|
Jun 01
2023
|
John R. Jacobsen CSO |
SELL
Open market or private sale
|
Direct |
18,750
-5.77%
|
$562,500
$30.78 P/Share
|
|
May 05
2023
|
Richard H Scheller Director |
SELL
Open market or private sale
|
Direct |
84,097
-90.89%
|
$3,195,686
$38.51 P/Share
|
|
May 03
2023
|
Scott M. Robertson CFO & CBO |
SELL
Open market or private sale
|
Direct |
18,750
-8.65%
|
$675,000
$36.55 P/Share
|
|
May 03
2023
|
Lu Timothy CMO |
SELL
Open market or private sale
|
Direct |
10,000
-6.16%
|
$360,000
$36.54 P/Share
|
|
May 03
2023
|
Kevin Judice CEO |
SELL
Open market or private sale
|
Direct |
13,698
-1.68%
|
$493,128
$36.5 P/Share
|
|
May 01
2023
|
James Paul Scopa Director |
BUY
Bona fide gift
|
Indirect |
6,923
+18.43%
|
-
|
|
May 01
2023
|
James Paul Scopa Director |
SELL
Bona fide gift
|
Direct |
6,923
-31.29%
|
-
|